Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema
Anthony S Basile,1 Matthew M Hutmacher,2 Kenneth G Kowalski,2 Kuan Y Gandelman,3 Dana J Nickens1 1Clinical Pharmacology, Specialty Care Business Unit, Pfizer Inc, San Diego, CA, USA; 2Ann Arbor Pharmacometrics Group, Ann Arbor, MI, USA; 3Clinical Pharmacology, World Wide Biopharmaceuticals, Pfizer...
Main Authors: | Basile AS, Hutmacher MM, Kowalski KG, Gandelman KY, Nickens DJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-02-01
|
Series: | Clinical Ophthalmology |
Online Access: | http://www.dovepress.com/population-pharmacokinetics-of-pegaptanib-sodium-macugenreg-in-patient-peer-reviewed-article-OPTH |
Similar Items
-
Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
by: G. Querques, et al.
Published: (2009-01-01) -
Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema
by: Kiire CA, et al.
Published: (2015-12-01) -
A comparative debate on the various anti-vascular endothelial growth factor drugs: Pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin)
by: Nagpal Manish, et al.
Published: (2007-01-01) -
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
by: Udaondo P, et al.
Published: (2011-07-01) -
An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
by: Sivaprasad S, et al.
Published: (2014-08-01)